Genmab has filed a patent for a method of treating chronic lymphocytic leukemia (CLL) using a bispecific antibody that binds to CD3 and CD20. The method involves administering the antibody to human subjects at a dose ranging from 12-60 mg in 28-day cycles. GlobalData’s report on Genmab gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Genmab, Personalized cancer vaccines was a key innovation area identified from patents. Genmab's grant share as of September 2023 was 37%. Grant share is based on the ratio of number of grants to total number of patents.
Method of treating chronic lymphocytic leukemia using bispecific antibody
A recently filed patent (Publication Number: US20230312757A1) describes a method for treating chronic lymphocytic leukemia (CLL) in human subjects using a bispecific antibody. The bispecific antibody has two binding arms, one that binds to human CD3e and another that binds to human CD20. The antibody is administered to the subject at a dose ranging from 12-60 mg in 28-day cycles. The patent claims specify different doses for administration, including 24 mg and 48 mg.
The method involves administering the bispecific antibody once every week for 2.5 28-day cycles. After the weekly administration, the antibody is then administered once every two weeks for six 28-day cycles. Following this, the antibody is administered once every four weeks. Prior to administering the first weekly dose, a priming dose of the bispecific antibody is given in cycle 1 of the 28-day cycles. The priming dose is administered two weeks before the first weekly dose and is in the range of 0.05-0.35 mg.
In addition to the dosing regimen, the patent claims also cover the specific amino acid sequences of the variable heavy chain (VH) and variable light chain (VL) regions of the bispecific antibody. The patent further specifies that the bispecific antibody can be administered subcutaneously.
The method described in the patent is intended for the treatment of CLL in human subjects who are intolerant to a BTK inhibitor and have received at least two prior lines of antineoplastic therapy. The CLL may be relapsed and/or refractory to a BTK inhibitor. The bispecific antibody described in the patent is a full-length antibody with a human IgG1 constant region and an inert Fc region. The patent also mentions a specific bispecific antibody called epcoritamab, or a biosimilar thereof.
Overall, the patent describes a method for treating CLL using a bispecific antibody with specific binding arms and dosing regimens. The method is intended for patients who have not responded to or cannot tolerate a BTK inhibitor and have received prior antineoplastic therapy. The patent also covers the specific amino acid sequences of the antibody and its administration via subcutaneous injection.
To know more about GlobalData’s detailed insights on Genmab, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
